Abstract
In recent years we have seen a revolution in the development of monoclonal antibodies as pharmaceutical drugs. As one of its ringleaders, I shall relate how the revolution unfolded in the development of two antibodies, alemtuzumab and adalimumab, including the interplay of technology, intellectual property, business, and politics.
